缬沙坦联合氨氯地平或氢氯噻嗪对老年高血压患者血压变异性的影响

目的 比较缬沙坦联合氨氯地平或氢氯噻嗪对老年高血压患者血压变异性及一氧化氮、内皮素的影响.方法选取61例2、3级老年高血压患者,随机分为两组,分别给予缬沙坦+氨氯地平或缬沙坦+氢氯噻嗪行降压治疗,观察入选时、治疗第8周和第16周各种相关指示的变化.人选时检测血脂、空腹血糖、血尿酸,试验各个阶段监测24 h动态血压,检测血浆一氧化氮、内皮素水平.结果在患者入选时、治疗第8周和第16周三个时间点,缬沙坦+氨氯地平组和缬沙坦+氢氯噻嗪组24 h血压及白昼血压比较差异无统计学意义.治疗第16周,缬沙坦+氨氯地平组晨峰收缩压较缬沙坦+氢氯嚷嗪组明显降低(22.6±8.8)mm Hg(1 mm Hg=0.133 kPa)比(26.3±13.7)mm Hg,P＜0.05];缬沙坦+氨氯地平组及缬沙坦+氢氯噻嗪组24 h收缩压变异性(SBPV)进行性降低缬沙坦+氨氯地平组:(12.5±2.8)mm Hg比(10.2 ±2.2)mm Hg比(8.8±1.6)mm Hg,P＜0.01;缬沙坦±氢氯噻嗪组:(12.5±2.5)mmHg比(10.7±2.2)mm Hg比(9.6±2.0)mmHg,P＜0.01],缬沙坦+氨氯地平组及缬沙坦+氢氯噻嗪组白昼SBPV明显降低缬沙坦+氨氯地平组:(12.2±3.0)mm Hg比(10.1±2.3)mm Hg比(8.4±1.9)mm Hg,P＜0.01;缬沙坦+氢氯噻嗪组:(11.8±2.7)mm Hg比(10.4±1.9)mm Hg比(9.6±2.2)mm Hg,P＜0.01],缬沙坦+氨氯地平组24 h舒张压变异性(DBPV)显著降低(15.5±3.4)mm Hg比(13.0±3.5)mm Hg比(12.3±2.5)mm Hg,P＜0.01],缬沙坦+氢氯噻嗪组24 h DBPV无显著性变化;缬沙坦+氨氯地平组第16周白昼SBPV低于缬沙坦+氢氯噻嗪组(8.4±1.9)mm Hg比(9.6 ±2.2)mm Hg,p＜0.05],缬沙坦+氨氯地平第8周、第16周的24 h DBPV、白昼DBPV低于缬沙坦+氢氯噻嗪组(P ＜0.01～0.05);缬沙坦+氨氯地平组一氧化氮进行性升高(27.3±13.6)μmol/L比(47.2±16.3)μmol/L比(69.5±18.9)μmol/L,P＜0.01]、内皮素进行性降低(45.3±8.0)ng/L比(37.4±3.9)ng/L比(34.2±4.4)ng/L,P＜0.01];缬沙坦+氢氯噻嗪组一氧化氮进行性升高(33.5±13.9)μmol/L 比(49.7±21.9)μmol/L比(66.7 ±24.7)μmol/L,P＜0.01]、内皮素显著降低(46.6±10.4)ng/L比(37.0±5.4)ng/L比(36.1±8.2)ng/L,P＜0.01].治疗第8周,缬沙坦+氨氯地平组收缩压变异性的降幅与一氧化氮的升幅有相关性(r =0.401,P=0.025).结论缬沙坦联合氨氯地平或氢氯噻嗪均能降低老年高血压患者血压变异性、改善血管内皮功能,缬沙坦联合氨氯地平可能更适合于老年高血压患者.

Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients

Objective To compare the effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation and plasma nitric oxide(NO)and endothelin(ET)in elderly hypertensive patients.Methods A total of 61 elderly patients with grade 2 or 3 hypertension were randomized into valsartan + amlodipine(the amlodipine group,n =31)or valsartan + hydrochlorothiazide (the hvdrochlorothiazide group,n =30)group.Blood lipids,fasting plasma glucose and uric acid were determined before the treatment.24-hour dynamic blood pressure,NO and ET were monitored at baseline,8 and 16 weeks after treatment.Results 24 hours blood pressure and daytime blood pressure were similarbetween two groups at all 3 time points.At 16 weeks,morning systolic blood pressure surge was significantly lower in amlodipine group than in hydrochlorothiazide group(22.6 ±8.8)mm Hg(1 mm Hg =0.133 kPa)vs.(26.3 ± 13.7)mm Hg,P ＜ 0.05].24 hours systolic blood pressure variability(SBPV)decreased progressively in both groupsthe amlodipine group:(12.5 ±2.8)mm Hg vs.(10.2 ±2.2)mm Hg vs.(8.8 ±1.6)mm Hg,P ＜0.01;the hydrochlorothiazide group:(12.5 ±2.5)mm Hg vs.(10.7 ±2.2)mm Hg vs.(9.6 ±2.0)mm Hg,P ＜ 0.01].Daytime SBPV also decreased progressively in both groupsthe amlodipinegroup:(12.2±3.0)mm Hgvs.(10.1 ±2.3)mm Hgvs.(8.4±1.9)mm Hg,P＜0.01;the hydrochlorothiazide group:(11.8 ± 2.7)mm Hg vs.(10.4 ± 1.9)mm Hg vs.(9.6 ± 2.2)mm Hg,P ＜0.01].24 hours diastolic blood pressure variability(DBPV)was significantly reduced post therapy in the amlodipine group(15.5 ±3.4)mm Hgvs.(13.0±3.5)mm Hgvs.(12.3±2.5),P＜0.01]but not in the hydrochlorothiazide group.NO increased progressively(27.3 ± 13.6)μmol/L vs.(47.2 ± 16.3)μmol/L vs.(69.5 ± 18.9)μmol/L in the anlodipine group,P ＜ 0.0l ;(33.5 ± 13.9)μmol/L vs.(49.7 ±21.9)μmol/L vs.(66.7 ± 24.7)μmol/L in the hydrochlorothiazide group,P ＜ 0.01]and ET decreased progressively(45.3 ±8.0)ng/L vs.(37.4 ±3.9)ng/L vs.(34.2 ±4.4)ng/l in the arnlodipine group,P ＜0.01 ;(46.6 ± 10.4)ng/L vs.(37.0 ± 5.4)ng/L vs.(36.1 ± 8.2)ng/L in the hydrochlorothiazide group,P ＜ 0.01]in both groups.Conclusion Valsartan in combination with amlodipine or hydroehlorothiazide can both effectively lower BPV in elderly hypertensive patients and improve the vascular endothelial function and the former regimen is more suitable for elderly hypertensive patients.